This 2023 systematic review and meta-analysis found that supplemental vitamin D doses of 3200–4000 IU/day were associated with a higher risk of hypercalcemia. In the pooled analysis of 10 studies reporting hypercalcemia, the relative risk was 2.21 (95% CI: 1.26–3.87), and the authors concluded that this dose range "appears to increase the risk of hypercalcemia" and is "not completely safe."

The PubMed record identifies the article as a 2023 systematic review and meta-analysis on long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events. The article reports that this dose range was associated with increased hypercalcemia risk, with the abstract stating that 3200–4000 IU/day appears to increase the risk of hypercalcemia.

Among 20 studies that reported hypercalcemia, 10 found no cases in either group, while the remaining studies showed a significantly higher risk with vitamin D supplementation. The review reports 34 cases in 5,364 vitamin D recipients versus 14 cases in 6,749 controls, corresponding to an RR of 2.21.

PubMed indexes the 2023 meta-analysis on long-term supplementation with 3200 to 4000 IU/day of vitamin D and adverse events. The indexed article is the specific study underlying the claim that this daily dose range was linked to higher hypercalcemia risk.

The fact sheet notes that the tolerable upper intake level (UL) for vitamin D in adults is 4,000 IU per day and that intakes above this level might increase the risk of adverse health effects over time. It explains that taking very high doses of vitamin D for extended periods can cause hypercalcemia, with symptoms such as nausea, vomiting, muscle weakness, confusion, pain, loss of appetite, dehydration, and kidney stones. The NIH advises that people taking more than 4,000 IU/day of vitamin D under medical supervision should have their blood levels monitored to reduce the risk of toxicity, including hypercalcemia.

In a section on safety, this 2025 review notes that vitamin D supplementation is generally safe within recommended limits but excessive intake may cause hypercalcemia or nephrolithiasis. It cites the 2023 systematic review: "A recent meta-analysis of randomized controlled trials evaluating long-term supplementation with 3,200–4,000 IU/day of vitamin D3 reported an increased risk of hypercalcemia compared with placebo or lower-dose vitamin D, although the absolute risk was low (approximately 4 additional cases per 1,000 individuals)." The article emphasizes that this finding suggests the upper tolerable intake level may not be fully without risk in all individuals.

An updated 2024 systematic review examined long-term vitamin D supplementation at doses ≥ 2000 IU/day and safety outcomes including hypercalcemia. Subgroup analysis of trials using daily doses of 3200–4000 IU found a modest but statistically significant increase in hypercalcemia compared with placebo or lower-dose vitamin D, consistent with findings from the 2023 meta-analysis. The absolute risk increase was small, and most cases of hypercalcemia were asymptomatic and resolved after discontinuation of supplementation.

Harvard Health explains that excessive vitamin D can lead to hypercalcemia, where too much calcium builds up in the blood. It also notes that doses in the 2,000 IU to 4,000 IU range have been associated with increased fall risk in some studies, and that 4,000 IU per day is commonly treated as the upper safe limit unless medically supervised.

This randomized, double-blind trial assigned 2423 overweight/obese persons with prediabetes "to either 4000 IU of vitamin D₃ (the tolerable upper intake level for adults by the National Academy of Medicine) taken daily or matching placebo." In the results they state: "The overall frequency of protocol-specified AEs of interest, which included nephrolithiasis, hypercalcemia, hypercalciuria, or low estimated glomerular filtration rate, was low and did not differ by group." They conclude: "Vitamin D₃ supplementation at 4000 IU per day was safe and well tolerated among overweight/obese participants at high risk for diabetes who were appropriately monitored for safety. In this population, this dose of vitamin D₃ did not increase risk of AEs or SAEs, including those previously associated with vitamin D such as hypercalcemia, hypercalciuria, or nephrolithiasis."

The journal version of the 2023 meta-analysis reports that the upper tolerable intake level for vitamin D has been set at 4,000 IU/day, but that "considerable uncertainty remains" about safety. It states that this meta-analysis included 22 randomized controlled trials with 12,952 participants taking 3,200–4,000 IU/day for at least 6 months. The authors conclude: "Supplemental vitamin D doses of 3200–4000 IU/d appear to increase the risk of hypercalcemia and some other adverse events in a small proportion of individuals," based on a pooled relative risk for hypercalcemia of 2.21 and an estimated 4 additional hypercalcemia cases per 1,000 individuals.

The review states that supplements up to 4000 IU appear to be safe and not cause significant hypercalcemia in the general adult population. It notes that hypervitaminosis D can increase calcium absorption leading to hypercalcemia, hyperphosphatemia, suppressed parathyroid hormone, and hypercalciuria, particularly at very high doses or in susceptible individuals. The authors caution that thiazide diuretics and underlying renal dysfunction or hyperparathyroidism may increase the risk of vitamin D–associated hypercalcemia even at doses that are usually considered safe.

In the randomized trials included in this systematic review, vitamin D dosing was categorized into standard dose and high dose, with some regimens using the equivalent of several thousand IU per day. Across the studies examined, there were no reported cases of symptomatic hypercalcemia, nephrolithiasis, or kidney disease/renal failure in the vitamin D treatment groups at the doses used, although some asymptomatic hypercalcemia was observed. The authors conclude that while vitamin D supplementation is generally safe within recommended limits, monitoring may be warranted in higher-dose regimens and in populations at increased risk for hypercalcemia.

The Endocrine Society guideline notes that the tolerable upper intake level for vitamin D is generally 4,000 IU/day for adults, and that chronic intakes above this may increase the risk of adverse events including hypercalcemia. It refers to emerging evidence that even intakes at the UL (around 3,000–4,000 IU/day) may be associated with small increases in hypercalcemia in some randomized trials, emphasizing caution with long-term high-dose supplementation for primary prevention.

The NIH fact sheet explains: "The Food and Nutrition Board (FNB) established a tolerable upper intake level (UL) for vitamin D for adults of 4,000 IU (100 mcg) daily." It notes that "signs of toxicity are marked by serum 25(OH)D concentrations greater than 150 ng/mL (375 nmol/L)" and that "excessive intakes of vitamin D can lead to hypercalcemia, which can cause nausea, vomiting, weakness, and serious complications such as kidney damage." The fact sheet cites clinical trial data and mentions that while most trials at the UL have not reported high rates of toxicity, some meta-analyses have suggested a small increase in hypercalcemia and other adverse events at intakes near or above the UL.

This guideline-style review cites trial evidence on vitamin D safety and states that prespecified adverse events such as hypercalcemia were rare. It does not support a broad safety concern at routine doses, but it also discusses that higher vitamin D dosing may increase adverse effects in some contexts.

This 2024 guideline document advises against empiric vitamin D supplementation above the current dietary reference intake for disease prevention in healthy adults younger than 75 years. It includes discussion of evidence on adverse events and cites dose-related concerns in the vitamin D literature.

In nutrition guidance, 4,000 IU/day has often been treated as the tolerable upper intake level for adults, so a meta-analysis finding increased hypercalcemia risk in the 3,200–4,000 IU/day range is notable because it concerns doses near that upper boundary.